Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is a dominant player in the pharmaceutical industry, with a strong presence in both the generic and innovative medicine markets. Its wide distribution network, global presence, and diversified portfolio make it a resilient company with strong potential for growth. Their focus on developing biosimilars and innovative treatments in neurology and immunology, coupled with their strategic investments in research and development, position them well for long-term success. The imminent release of top-line data for their anti-IL-15 drug candidate, along with their recent acquisition of Emalex Biosciences and their continued growth in key products, indicate a promising future for the company. However, risks such as regulatory changes and pricing uncertainty must be closely monitored in the pharmaceutical industry.

Bears say

Teva Pharmaceutical Indus is facing potential challenges in the future due to impending pricing changes for its innovative medicine Austedo, as well as competition from oral JAK inhibitors which have adverse side effects. Additionally, the Austedo franchise saw strong sales growth in 1Q26, but this was mostly due to inventory drawdown rather than actual volume growth. However, there is potential for continued growth in the neurology and immunology therapeutic areas, which could be a positive for the company's financials in the long term.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.